Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRGNASDAQ:GYRENASDAQ:ONCTNASDAQ:UBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$1.46-11.0%$2.33$1.40▼$4.84$13.79M0.33317,262 shs130,064 shsGYREGyre Therapeutics$6.72-5.2%$10.93$6.17▼$19.00$630.95M1.9387,986 shs64,964 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$9.88$1.56M1.1857,435 shsN/AUBXUnity Biotechnology$1.03-3.2%$1.82$0.94▼$3.10$17.46M1.02114,628 shs10,113 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI-0.61%-13.68%-13.23%-21.53%-44.78%GYREGyre Therapeutics+10.61%-19.34%-37.97%-40.92%-58.27%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-94.32%UBXUnity Biotechnology+10.41%-11.67%-31.61%-7.02%-34.16%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRGBullfrog AI1.0526 of 5 stars0.05.00.00.02.21.70.0GYREGyre Therapeutics0.1875 of 5 stars0.00.00.00.02.81.70.0ONCTOncternal Therapeutics1.3344 of 5 stars3.10.00.00.00.00.81.3UBXUnity Biotechnology4.095 of 5 stars3.53.00.04.71.10.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 0.00N/AN/AN/AGYREGyre Therapeutics 3.00BuyN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsideUBXUnity Biotechnology 3.00Buy$5.33419.82% UpsideCurrent Analyst Ratings BreakdownLatest BFRG, ONCT, GYRE, and UBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/24/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.003/11/2025GYREGyre TherapeuticsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/10/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/10/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.001/10/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$60K229.10N/AN/A$0.43 per share3.40GYREGyre Therapeutics$105.76M5.95$0.13 per share50.49$0.18 per share37.33ONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05UBXUnity Biotechnology$240K72.11N/AN/A$1.69 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$5.36M-$0.86N/A∞N/AN/A-141.39%-124.63%4/4/2025 (Estimated)GYREGyre Therapeutics-$92.93M$0.05134.80∞N/A-84.57%-118.43%-71.97%5/8/2025 (Estimated)ONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/AUBXUnity Biotechnology-$39.86M-$1.53N/AN/AN/AN/A-119.70%-45.86%4/21/2025 (Estimated)Latest BFRG, ONCT, GYRE, and UBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 million3/14/2025Q4 2024BFRGBullfrog AIN/A-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/AUBXUnity BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A5.905.90GYREGyre TherapeuticsN/A3.723.29ONCTOncternal TherapeuticsN/A2.392.39UBXUnity BiotechnologyN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%GYREGyre Therapeutics23.99%ONCTOncternal Therapeutics16.05%UBXUnity Biotechnology29.49%Insider OwnershipCompanyInsider OwnershipBFRGBullfrog AI33.90%GYREGyre Therapeutics19.52%ONCTOncternal Therapeutics11.20%UBXUnity Biotechnology5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI49.42 million5.76 millionNot OptionableGYREGyre Therapeutics4093.61 million75.27 millionNo DataONCTOncternal Therapeutics302.96 million2.63 millionNo DataUBXUnity Biotechnology6016.87 million15.87 millionOptionableBFRG, ONCT, GYRE, and UBX HeadlinesRecent News About These CompaniesCorbus Pharmaceuticals (NASDAQ:CRBP) and Unity Biotechnology (NASDAQ:UBX) Critical ReviewMarch 31 at 1:17 AM | americanbankingnews.comHC Wainwright Has Negative Forecast for UBX FY2026 EarningsMarch 29, 2025 | americanbankingnews.comUnity Biotechnology price target lowered to $4 from $8 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology price target lowered to $4 from $6 at ChardanMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology (NASDAQ:UBX) Given New $4.00 Price Target at Chardan CapitalMarch 26, 2025 | americanbankingnews.comUnity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC WainwrightMarch 26, 2025 | americanbankingnews.comUnity Biotechnology announces results from ASPIRE Phase 2b study in DMEMarch 25, 2025 | markets.businessinsider.comUnity reports topline outcomes from trial of diabetic macular oedema therapyMarch 25, 2025 | msn.comUNITY Biotechnology tanks on mixed results for eye disease drugMarch 25, 2025 | thepharmaletter.comUBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyMarch 25, 2025 | zacks.comUNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular EdemaMarch 24, 2025 | finance.yahoo.comUnity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edemaMarch 24, 2025 | ophthalmologytimes.comUNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trialMarch 24, 2025 | msn.comUnity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock FallsMarch 24, 2025 | benzinga.comUNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular EdemaMarch 24, 2025 | globenewswire.comUNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025March 23, 2025 | globenewswire.comUnity Biotechnology announces upcoming trial data and new board of directors memberMarch 15, 2025 | ophthalmologytimes.comUnity Biotechnology appoints Hashad to board of directorsMarch 10, 2025 | markets.businessinsider.comUNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of DirectorsMarch 10, 2025 | markets.businessinsider.comUnity Biotechnology reports Q4 EPS (50c) vs. (28c) last yearMarch 7, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBFRG, ONCT, GYRE, and UBX Company DescriptionsBullfrog AI NASDAQ:BFRG$1.46 -0.18 (-10.98%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Gyre Therapeutics NASDAQ:GYRE$6.72 -0.37 (-5.22%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Oncternal Therapeutics NASDAQ:ONCT$0.53 0.00 (0.00%) As of 04/1/2025Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Unity Biotechnology NASDAQ:UBX$1.03 -0.03 (-3.21%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
